This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 6
  • /
  • Pivotal phase III SIERRA trial data showing 100% b...
News

Pivotal phase III SIERRA trial data showing 100% bone marrow transplant engraftment in patients treated with Iomab-B presented at the 2021 virtual SNMMI conference.- Actinium Pharmaceuticals.

Read time: 1 mins
Published:16th Jun 2021
Actinium Pharmaceuticals, Inc. highlighted data from its pivotal Phase III SIERRA trial for Iomab-B in an oral presentation at the 2021 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, which is to be held virtually from June 11th – 14th.

The SIERRA trial is the only randomized Phase III trial to offer potentially curative BMT as an option for patients with active, relapsed or refractory acute myeloid leukemia (r/r AML) age 55 and above, a patient population not considered eligible for BMT with standard non-targeted conditioning regimens. SNMMI Presentation Title: "Relationship of Marrow Radiation Dose and Timing of Engraftment for Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia" : Presenter: Susan Passalaqua, MD, Banner MD Anderson Cancer Center. SNMMI Presentation Highlights : i. 100% BMT and engraftment rate for patients receiving a therapeutic dose of Iomab-B compared to 18% of patients receiving physician's choice of salvage therapy on the control arm. ii.79% of all patients enrolled on SIERRA were able to proceed to BMT despite being a patient population not considered eligible for BMT with standard approaches. iii. Iomab-B delivers high amounts of targeted radiation to the bone marrow with minimal impact on other organs resulting in lower rates and severity of adverse events.

Condition: AML/Bone Marrow Transplant
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.